SOURCE-LINKED STUDY SUMMARY
Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults.
Abstract summarizedQuality not appraised
- What was studied
- Tested the safety and vascular effects of the mitochondria-targeted antioxidant MitoQ in older adults with impaired endothelial function.
- Who / model studied
- Twenty healthy adults aged 60–79 years with impaired brachial-artery flow-mediated dilation completed a double-blind crossover study.
- Studied dose & schedule
- Participants received oral MitoQ at 20 mg/day or placebo for 6 weeks per treatment period.
- What the study found
- Flow-mediated dilation was 42% higher after MitoQ than placebo, supporting a vascular-endothelial effect in this older cohort.
- Limitations & context
- This small, short crossover study assessed surrogate vascular outcomes rather than clinical events. MitoQ was well tolerated, but larger confirmatory trials are needed.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1161/hypertensionaha.117.10787